Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
Georg PfeilerDominik HlauschekErica L MayerChristine DeutschmannStephanie Kacerovsky-StroblMiguel MartinJane Lowe MeiselNicholas ZdenkowskiSibylle LoiblMarija BalićHaeseong ParkAleix PratClaudine IsaacsEmilio BajettaJustin M BalkoMerixtell Bellet-EzquerraJudith M BlissHarold J BursteinFatima CardosoHannes FohlerTheodoros FoukakisKaren A GelmonMatthew P GoetzTufia C HaddadHiroji IwataJacek JassemSoo-Chin LeeBarbro LinderholmMaartje LosEleftherios P P MamounasKathy D MillerPatrick G MorrisElisabetta MunzoneEinav Nili Gal-YamAlistair RingLois E ShepherdChristian F SingerChristoph ThomssenLing Ming TsengPinuccia ValagussaEric P WinerAntonio C WolffFrancesco RaveraJana Machacek-LinkCéline SchurmansXin HuangEric GauthierChristian FeslAmylou C DueckAngela M DeMicheleMichael Gnantnull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
This preplanned analysis of the PALLAS trial demonstrates a significant impact of BMI on side effects, dose reductions, early treatment discontinuation, and relative dose intensity. Additional long-term follow-up will further evaluate whether BMI ultimately affects outcome.